Xenon Pharmaceuticals Company Profile (NASDAQ:XENE)

Analyst Ratings

Consensus Ratings for Xenon Pharmaceuticals (NASDAQ:XENE) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.50 (97.01% upside)

Analysts' Ratings History for Xenon Pharmaceuticals (NASDAQ:XENE)
Show:
DateFirmActionRatingPrice TargetActions
5/11/2016Jefferies GroupReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Canaccord GenuityReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015SEB Equity ResearchReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2014Wells Fargo & Co.Initiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Xenon Pharmaceuticals (NASDAQ:XENE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116($0.21)($0.23)$3.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q415($0.16)($0.27)$4.65 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.02)($0.27)$4.65 million$4.29 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.16)($0.07)$4.23 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115$0.14($0.30)$4.65 million$4.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q4($0.09)$1.57ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/16/2014$0.41$1.69ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.21)($0.21)($0.21)
Q2 20161($0.24)($0.24)($0.24)
Q3 20161($0.27)($0.27)($0.27)
Q4 20161($0.27)($0.27)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Xenon Pharmaceuticals (NASDAQ:XENE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Xenon Pharmaceuticals (NASDAQ:XENE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/24/2016Ian MortimerCFOBuy5,300$6.22$32,966.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2015Y. Paul GoldbergVPSell22,149$8.88$196,683.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Xenon Pharmaceuticals (NASDAQ:XENE)
DateHeadline
07/25/16 03:48 PMXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update - [at noodls] - BURNABY, British Columbia, July 25, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 second quarter ...
06/08/16 06:58 AMXenon Pharmaceuticals Presents Corporate Update and Highlights Its Proprietary Therapeutic Programs at the Jefferies 2016 Healthcare Conference - [at noodls] - BURNABY, British Columbia, June 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that Dr. Simon Pimstone, Xenon's President and ...
06/03/16 03:32 PMXENON PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/02/16 07:25 AMXenon Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - BURNABY, British Columbia, June 02, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President ...
05/17/16 03:34 PMXenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 04:28 PMXenon Pharmaceuticals reports 1Q loss -
05/10/16 03:30 PMXenon Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today -
05/10/16 03:18 PMXenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - BURNABY, British Columbia, May 10, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended ...
05/10/16 06:07 AMQ1 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close -
05/02/16 03:30 PMXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results and Provide Corporate Update - [at noodls] - BURNABY, British Columbia, May 02, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 first quarter ...
04/07/16 10:41 AMEdited Transcript of XENE earnings conference call or presentation 8-Mar-16 9:30pm GMT -
04/04/16 04:00 PMXenon Names Dr. Raymond J. Winquist as Head, Translational Research - [at noodls] - BURNABY, British Columbia, April 04, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Raymond J. Winquist has been ...
03/31/16 04:22 PMXenon Pharma Will Offer Business, Milestone Update at Needham Conference - Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a business update, including progress toward milestones, at the Needham Healthcare Conference at 12:50 pm ET on Tuesday, April 12, 2016, in New York City. Anticipated Milestones Xenon's partner Teva Pharmaceutical Industries Ltd. is currently conducting a randomized, double-blind, placebo-controlled Phase 2b clinical trial for TV-45070 in patients with post-herpetic neuralgia. Previously, the Company had anticipated results in the second half of 2016; however, Teva updated its forecast and now expects results in the first half of 2017. Xenon's partner Genentech, a member of the Roche Group, is currently conducting two Phase 1 clinical trials for GDC-0276 and GDC-0310, which are both oral, selective Nav1.7 small-molecule inhibitors being developed for the potential treatment ...Full story available on Benzinga.com
03/31/16 03:55 PMXenon Pharmaceuticals to Provide Business and Milestone Update at Needham Healthcare Conference - [at noodls] - BURNABY, British Columbia, March 31, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President ...
03/01/16 08:25 PMXenon Pharmaceuticals To Host Conference Call And Webcast To Discuss 2015 Financial Results And Provide Corporate Update - BURNABY, British Columbia, March 01, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2015 financial and operating results after the close of U.S ...
02/26/16 12:48 PMXenon Pharmaceuticals Inc. (XENE) Broker Views - Risers & Fallers - Xenon Pharmaceuticals Inc. (XENE) Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Xenon Pharmaceuticals Inc. (XENE). According to the latest broker reports outstanding on Thursday 25th of February, 2 analysts have a rating of “strong buy”, 0 ...
02/18/16 03:24 PMXenon Pharmaceuticals, Inc.: Price momentum supported by strong fundamentals -
02/10/16 07:00 AMXenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne - [GlobeNewswire] - BURNABY, British Columbia, Feb. 10, 2016-- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that it has commenced dosing patients in a Phase 2 clinical trial of XEN801, ...
02/09/16 07:00 AMXenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery - [GlobeNewswire] - BURNABY, British Columbia, Feb. 09, 2016-- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that Dr. James R. Empfield has been named as Senior Vice President, Drug ...
02/02/16 01:45 PMPrice Target Update On Xenon Pharmaceuticals Inc. (XENE) - Risers & Fallers - Price Target Update On Xenon Pharmaceuticals Inc. (XENE)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Xenon Pharmaceuticals Inc. (XENE). According to the latest broker reports 2 analysts have a rating of “buy”, 0 analysts “outperform”, 0 analysts “hold”, 0 analysts ...
01/21/16 12:34 PMXenon Pharmaceuticals Inc. (XENE) Recent Analyst Updates - Risers & Fallers - Xenon Pharmaceuticals Inc. (XENE) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Xenon Pharmaceuticals Inc. (XENE). According to the latest broker reports outstanding on Thursday 21st January, 2 analysts have a rating of “strong buy”, 0 analysts ...
12/23/15 12:08 PMXenon Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/17/15 01:43 PMXenon and Genentech Publish in Science the 3-D Crystal Structure of a Novel Nav1.7 Compound Binding Site Enabling the Development of Potent Selective Inhibitors to Treat Pain - [at noodls] - , (GLOBE NEWSWIRE) -- (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced publication of a key article in Science by researchers at Xenon and Genentech describing for the first time ...
12/08/15 12:17 PMXENON PHARMACEUTICALS INC. Financials -
12/08/15 09:59 AMShould You Buy Energy Focus Inc (EFOI)? -
11/12/15 03:46 PMXenon Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference - [at noodls] - BURNABY, British Columbia, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President ...
11/10/15 04:00 PMXenon Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today -
11/10/15 03:56 PMXenon Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update - [at noodls] - Progress Includes Initiation of XEN801 Phase 1 Clinical Trial and Achievement of Milestones in Genentech Nav1.7 Clinical Program and Pain Genetics Collaboration Conference Call/Webcast Today at 5:00 p.m. ...
11/10/15 03:47 PMXenon Pharmaceuticals reports 3Q loss -
11/10/15 03:32 PMXENON PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -

Social

About Xenon Pharmaceuticals

Xenon Pharmaceuticals logoXenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company's platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XENE
  • CUSIP:
Key Metrics:
  • Previous Close: $7.36
  • 50 Day Moving Average: $6.91
  • 200 Day Moving Average: $7.02
  • P/E Ratio: N/A
  • P/E Growth: -0.44
  • Market Cap: $106.01M
  • Beta: 1.07
  • Current Year EPS Consensus Estimate: $-1.62 EPS
  • Next Year EPS Consensus Estimate: $-0.55 EPS
Additional Links:
Xenon Pharmaceuticals (NASDAQ:XENE) Chart for Wednesday, July, 27, 2016